275 related articles for article (PubMed ID: 34589603)
1. Recent advances in cellular biosensor technology to investigate tau oligomerization.
Lo CH
Bioeng Transl Med; 2021 Sep; 6(3):e10231. PubMed ID: 34589603
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
[TBL] [Abstract][Full Text] [Related]
3. The role of wild-type tau in Alzheimer's disease and related tauopathies.
Lo CH; Sachs JN
J Life Sci (Westlake Village); 2020 Dec; 2(4):1-17. PubMed ID: 33665646
[TBL] [Abstract][Full Text] [Related]
4. Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy.
Shin S; Kim D; Song JY; Jeong H; Hyeon SJ; Kowall NW; Ryu H; Pae AN; Lim S; Kim YK
Prog Neurobiol; 2020 Feb; ():101782. PubMed ID: 32105751
[TBL] [Abstract][Full Text] [Related]
5. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
6. Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get.
Frey B; AlOkda A; Jackson MP; Riguet N; Duce JA; Lashuel HA
J Neurochem; 2021 May; 157(4):872-888. PubMed ID: 32772367
[TBL] [Abstract][Full Text] [Related]
7. Novel antibody against low-n oligomers of tau protein promotes clearance of tau in cells via lysosomes.
Chandupatla RR; Flatley A; Feederle R; Mandelkow EM; Kaniyappan S
Alzheimers Dement (N Y); 2020; 6(1):e12097. PubMed ID: 33145390
[TBL] [Abstract][Full Text] [Related]
8. Oligomer Diversity during the Aggregation of the Repeat Region of Tau.
Kjaergaard M; Dear AJ; Kundel F; Qamar S; Meisl G; Knowles TPJ; Klenerman D
ACS Chem Neurosci; 2018 Dec; 9(12):3060-3071. PubMed ID: 29953200
[TBL] [Abstract][Full Text] [Related]
9. Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors.
Despres C; Di J; Cantrelle FX; Li Z; Huvent I; Chambraud B; Zhao J; Chen J; Chen S; Lippens G; Zhang F; Linhardt R; Wang C; Klärner FG; Schrader T; Landrieu I; Bitan G; Smet-Nocca C
ACS Chem Biol; 2019 Jun; 14(6):1363-1379. PubMed ID: 31046227
[TBL] [Abstract][Full Text] [Related]
10. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease.
Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Sarmiento J; Troncoso J; Jackson GR; Kayed R
FASEB J; 2012 May; 26(5):1946-59. PubMed ID: 22253473
[TBL] [Abstract][Full Text] [Related]
11. Different Amyloid-β Self-Assemblies Have Distinct Effects on Intracellular Tau Aggregation.
Shin WS; Di J; Murray KA; Sun C; Li B; Bitan G; Jiang L
Front Mol Neurosci; 2019; 12():268. PubMed ID: 31787880
[TBL] [Abstract][Full Text] [Related]
12. Split GFP complementation assay for quantitative measurement of tau aggregation in situ.
Chun W; Waldo GS; Johnson GV
Methods Mol Biol; 2011; 670():109-23. PubMed ID: 20967587
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation at Ser289 Enhances the Oligomerization of Tau Repeat R2.
Man VH; He X; Han F; Cai L; Wang L; Niu T; Zhai J; Ji B; Gao J; Wang J
J Chem Inf Model; 2023 Feb; 63(4):1351-1361. PubMed ID: 36786552
[TBL] [Abstract][Full Text] [Related]
14. TAUCON and TAUCOM: A novel biosensor based on fluorescence resonance energy transfer for detecting tau hyperphosphorylation-associated cellular pathologies.
Ahn S; Suh JS; Jang YK; Kim H; Han K; Lee Y; Choi G; Kim TJ
Biosens Bioelectron; 2023 Oct; 237():115533. PubMed ID: 37517333
[TBL] [Abstract][Full Text] [Related]
15. Cell-based Models To Investigate Tau Aggregation.
Lim S; Haque MM; Kim D; Kim DJ; Kim YK
Comput Struct Biotechnol J; 2014 Nov; 12(20-21):7-13. PubMed ID: 25505502
[TBL] [Abstract][Full Text] [Related]
16. Tau oligomers and aggregation in Alzheimer's disease.
Meraz-Ríos MA; Lira-De León KI; Campos-Peña V; De Anda-Hernández MA; Mena-López R
J Neurochem; 2010 Mar; 112(6):1353-67. PubMed ID: 19943854
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress.
Kim JH; Kim E; Choi WH; Lee J; Lee JH; Lee H; Kim DE; Suh YH; Lee MJ
Mol Pharm; 2016 Jun; 13(6):2039-48. PubMed ID: 27120117
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau
Lim S; Shin S; Sung Y; Lee HE; Kim KH; Song JY; Lee GH; Aziz H; Lukianenko N; Kang DM; Boesen N; Jeong H; Abdildinova A; Lee J; Yu BY; Lim SM; Lee JS; Ryu H; Pae AN; Kim YK
Exp Mol Med; 2023 Mar; 55(3):612-627. PubMed ID: 36914856
[TBL] [Abstract][Full Text] [Related]
19. Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model: This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get". The articles are accompanied by a Preface "How good are cellular models?".
Lashuel HA
J Neurochem; 2021 May; 157(4):891-898. PubMed ID: 33336386
[TBL] [Abstract][Full Text] [Related]
20. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
